CJC-1295: two early trials and limited clinical evidence

What this comes down to

• One 2006 publication in the Journal of Clinical Endocrinology and Metabolism reported two randomized trials. Our stated search found one indexed randomized-trial report.
• It measured growth hormone and IGF-I, not body composition, recovery or sleep. Growth hormone rose 2- to 10-fold and IGF-I 1.5- to 3-fold, with a half-life of about six to eight days.
• The two trials reported no serious adverse reactions. The FDA's compounding entry names increased heart rate and systemic vasodilatory reaction as serious adverse events it has identified.
• It is sold almost exclusively as a blend with ipamorelin, a combination for which our stated search found no randomized-trial reports.

What the two early trials measured

CJC-1295 is a growth-hormone-releasing hormone analog engineered to last. Our stated PubMed search found 33 records and one indexed randomized-trial report^[3]. The 2006 paper reports two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, one running 28 days and the other 49^[1]. A single subcutaneous injection produced dose-dependent rises in mean plasma growth hormone of two- to tenfold lasting six days or more, and in IGF-I of 1.5- to threefold lasting nine to eleven days. The estimated half-life was 5.8 to 8.1 days. After repeat dosing, mean IGF-I stayed above baseline for up to 28 days. No serious adverse reactions were reported.

The indexed randomized-trial report. A PubMed search finds 1 result; the same search for semaglutide finds 316.

What the FDA has that the trial does not

The agency's compounding page, face-dated April 22, 2026, carries a short entry that does not match the trial's safety line^[2].

“Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”

^[2]

The two are not in conflict in the way they first look. A 2006 trial in a few dozen healthy volunteers is not powered to find an uncommon serious event, and the FDA is not restricted to published trials — it sees adverse event reports. What the pairing tells you is that the total human safety base for this peptide is two small trials and the safety information summarized by FDA; the agency does not quantify that broader evidence in this entry. The entry sits in the withdrawn-nominations table, which removes the substance from the queue for the bulks list and leaves the text published. Our status table records that placement for every peptide on these menus.

Nobody sells it alone

Across the 387 sellers we review, one priced line names CJC-1295, and it is the same blended protocol that carries ipamorelin, from Live Vital. That is worth holding onto when a page cites the 2006 numbers at you: the trial gave CJC-1295 by itself. The ipamorelin record is separate, and it is a trial that missed. Adding them together produces a product neither result describes.

There is no approved product with CJC-1295 as an active ingredient — Drugs@FDA returns nothing for it by ingredient, while the same search returns one application for tesamorelin and two for glutathione^[4]. So what a company dispenses is a compounded preparation, and the compounding questions apply: which pharmacy, which grade of material, and what any testing they mention actually covered.

Questions people actually ask